• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Diabetes and weight-loss device maker GI Dynamics eyes $102 million in a rough market

Diabetes and weight-loss device maker GI Dynamics eyes $102 million in a rough market

August 22, 2011 By MassDevice staff

GI Dynamics

GI Dynamics is optimistic that it can raise at least $86 million through its initial public offering in Australia, which is set to close this week.

The Lexington, Mass.-based obesity and Type II diabetes treatment company is aiming for between $80 to $95 million AUS according to regulatory filings, which is about $86 million to $102 million USD.

If it hits the higher mark, GI Dynamics’ IPO will be the second largest this year for Australia, behind the $200 million IPO for Collins Foods, The Australian reported.

"We continue to be excited by the response that we have seen and heard and we’re pushing forward," CEO Stuart Randle told the paper. "We’re quite optimistic."

Read more of MassDevice.com’s coverage of GI Dynamics.

GI Dynamics first filed a prospectus with Australian regulators on August 3, naming med-tech goliath Medtronic Inc. (NYSE:MDT) as a repeat investor. Regulatory documents showed that Medtronic, which previously invested $15 million, intended to be part of a private placement of $19.7 million AUS, about $20.7 million USD.

Other GI Dynamics past investors include Johnson & Johnson Development Corp., along with big venture capital firms Advanced Technology Ventures, Domain, Polaris Ventures and Cutlass Capital. All but JNJ are expected to participate in the private placement. About $6 million of the private placement will be convertible notes the company floated in the early summer under a bridge loan with current investors.

GI Dynamics’ EndoBarrier gastrointestinal sleeve won Australian approval for treatment of type 2 diabetes and obesity late last month. The device won CE Mark in Dec., 2009, for six months of treatment, which prompted a $15 million investment from Minneapolis, Minn.-based medical device giant Medtronic Inc. (NYSE:MDT), which joined other investors in backing the firm as it prepared for commercial launch in the European Union.

The EndoBarrier is a plastic sleeve inserted endoscopically into the small intestine, where it slows the uptake of nutrients from food to induce weight loss and help control the symptoms of diabetes.

The device can be implanted without surgery, which company president & CEO Stuart Randle views as the next wave for medical devices. "I think the next generation of technologies is going to be combinations of devices, combinations of drugs and combinations of devices and drugs, all focused on effecting multiple mechanisms of action simultaneously — and less invasively than surgery," Randle told MassDevice in a June 2009 interview.

Filed Under: Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: GI Dynamics

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy